cris.boxmetadata.label.title
Addressing social determinants to end tuberculosis
cris.boxmetadata.label.dateissued
24 browse.startsWith.months.march 2018
cris.boxmetadata.label.accesslevel
open access
cris.boxmetadata.label.resourcetype
editorial
cris.boxmetadata.label.authors
Wingfield T.
TOVAR HUAMANI, MARCO ANTONIO
Saunders M.J.
DATTA, SUMONA
EVANS, ANNABLE CARLTON
Asociación Benéfica PRISMA
Asociación Benéfica PRISMA
Asociación Benéfica PRISMA
cris.boxmetadata.label.publisher
Lancet Publishing Group
cris.boxmetadata.label.citationstartpage
1129
cris.boxmetadata.label.citationendpage
1132
cris.boxmetadata.label.volume
391
cris.boxmetadata.label.issue
10126
cris.boxmetadata.label.language
English
cris.boxmetadata.label.ocdeknowledgeArea
Epidemiología Políticas de salud, Servicios de salud
cris.boxmetadata.label.doi
10.1016/S0140-6736(18)30484-7
cris.boxmetadata.label.scopusidentifier
2-s2.0-85044110272
cris.boxmetadata.label.pubmedidentifier
29595481
cris.boxmetadata.label.source
The Lancet
cris.boxmetadata.label.containerissn
0140-6736
cris.boxmetadata.label.sponsor
CAE and MAT were involved in the ISIAT study and we are all involved in the HRESIPT and CRESIPT studies discussed here. TW was a winner of The Academy of Medical Sciences– Lancet Young Investigator Prize in 2017. We declare no other competing interests. We, the IFHAD group, receive funding from the Wellcome Trust, Department for International Development Civil Society Challenge Fund, Joint Global Health Trials consortium, Bill & Melinda Gates Foundation, Imperial College National Institutes of Health Research Biomedical Research Centre, Foundation for Innovative New Diagnostics, Sir Halley Stewart Trust, WHO, TB REACH, National Institute for Health Research (UK), Academy of Medical Sciences, and IFHAD.
peru-layout.shadow-copies Directorio de Producción Científica Scopus